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Background: FOXE1 and NKX2-1 are two known genetic risk factors for the predisposition to 
sporadic papillary thyroid carcinoma (PTC) in Europeans, but their association in other 
ethnicities is still unknown. 
Objective: We aim to examine the association of the two genes with Japanese sporadic PTC, 
which exhibits high BRAFV600E mutation rate. 
Methods: 507 Japanese sporadic PTC cases and 2,766 controls were genotyped for rs965513 
(FOXE1) and rs944289 (NKX2-1). PTC cases were also examined for their BRAFV600E 
mutational status. 
Results: We confirmed the association of both rs965513 (p=1.27×10-4, OR=1.69, 95% CI: 
1.29-2.21) and rs944289 (p=0.0121, OR=1.21, 95% CI: 1.04-1.39) with the risk of sporadic PTC. 
Subgroup analysis based on the BRAF mutational status showed strong association of rs965513 
with BRAFV600E-positive cases (p=2.26x10-4, OR=1.72, 95% CI: 1.29-2.29), but not with 
BRAFV600E-negative cases (p=0.143, OR=1.52, 95% CI: 0.87-2.65). However, there was no 
difference in the observed effect size between both subgroups. For rs944289, both subgroups 
showed marginal association (p=0.0585, OR=1.17, 95% CI: 0.99-1.37 for BRAFV600E-positive 
cases, and p=0.0492, OR=1.35, 95% CI: 1.00-1.81 for BRAFV600E-negative cases). 
Conclusions: Both FOXE1 and NKX2-1 were associated with the increased risk of sporadic 




Papillary thyroid carcinoma (PTC) is the most common malignant tumor in endocrine organs, 
and the only well-known environmental risk factor is exposure to ionizing radiation. Genetic 
polymorphisms have been shown to contribute to individual susceptibility to PTC.[1] The 
identification and further assessment of the relevant genetic variations are important for 
understanding the potential mechanisms involved in thyroid carcinogenesis. 
 
Recently, two genome-wide association (GWA) studies on thyroid cancer have been achieved. 
The first study dealt with sporadic thyroid cancer in Icelandic population using 192 and 37,196 
cases and controls, respectively, followed by a replication study in individuals of European 
descent.[2] The FOXE1 (TTF2) gene on 9q22.33 (p=1.7×10-27, odds ratio [OR]=1.75, 95% 
confidence interval [CI]: 1.59-1.94 for rs965513) and NKX2-1 (TTF1) on 14q13.3 (p=2.0×10-9, 
OR=1.37, 95% CI: 1.24-1.52 for rs944289) showed the strongest association signals. Both genes 
encode thyroid-specific transcription factors and appear to contribute to an increased risk of both 
PTC and follicular thyroid carcinoma (FTC). The second GWA study focused on 
radiation-related PTC using 667 young patients exposed to radioiodine fallouts during childhood 
and 1,275 age-matched control subjects residing in the radiocontaminated regions of Belarus at 
the time of the Chernobyl accident.[3] In this study, the FOXE1 gene showed strong association 
with radiation-related PTC (p=4.8×10-12, OR=1.65, 95% CI: 1.43-1.91 for rs965513) whereas no 
association was found with NKX2-1 (p=0.17, OR=1.13, 95% CI: 0.95-1.36 for rs944289). These 
results demonstrate that FOXE1 is a major genetic determinant of predisposition to thyroid 
carcinoma regardless of etiology and age. In contrast, NKX2-1 may be associated only with adult 
sporadic PTC. Furthermore, the involvement of these genes in thyroid carcinogenesis is yet to be 
examined in non-European populations. 
 
Thyroid carcinoma in the Japanese population shows distinct characteristics: higher incidence of 
PTC than in European populations, the vast majority of PTCs are low-risk tumors with classic 
papillary morphology, and higher BRAFV600E-positive rate (~80%) than in European populations 
(~50%).[4-8] Similar findings have also been observed in the Korean population.[9] These 
characteristics are presumably due to high iodine intake, since distribution of thyroid carcinoma 
type seems to be related to the intake of iodine: more aggressive follicular and anaplastic 
carcinomas in iodine-deficient areas and more papillary carcinomas in iodine-rich areas.[10, 11] 
A recent study demonstrated significant association between the prevalence of BRAFV600E 
mutation and high iodine intake.[12] The BRAFV600E mutation is the most prevalent genetic 
alteration in adult sporadic PTC and is related to aggressive clinicopathological characteristics 
including extrathyroidal invasion, lymph node metastasis, advanced tumor stages, and poorer 
prognosis.[8] This mutation is also observed in micropapillary carcinomas and may thus be an 
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early event in thyroid carcinogenesis. 
 
In this study, we aimed to examine the association of the former-identified genetic loci, namely, 
FOXE1 and NKX2-1, with PTC in a Japanese case-control series. In addition, we have evaluated 





A total of 509 patients with sporadic PTC (mean±SD age 51.3±16.0 years, range 13-87 years; 
84.4% women) were recruited from Kuma Hospital (Kobe, Japan). Histological diagnosis was 
performed by a thyroid pathologist (MH). 2,766 Japanese individuals were collected as 
population controls at Kyoto University. All patients and controls have no history of radiation 
exposure. The protocol was approved by the ethics committees of Nagasaki University, Kuma 
Hospital, and Kyoto University. 
 
DNA extraction and BRAF status screening 
DNA from PTC subjects was extracted from formalin-fixed paraffin-embedded (FFPE) primary 
tumor tissues using QIAamp DNA mini kit (QIAGEN, Tokyo, Japan) according to the 
manufacturer’s protocol. DNAs with sufficient quality for genotyping and sequencing were 
obtained from 507 out of 509 PTC specimens. BRAF status was screened by direct DNA 
sequencing. Primer sequences used for PCR and sequencing were: BRAFi14F, 
5’-ACATACTTATTGACTCTAAGAGGAAAGATGAA-3’ and BRAFi15R, 
5’-GATTTTTGTGAATACTGGGAACTATGA-3’. PCR products were treated with ExoSAP-IT 
PCR clean-up reagent (GE Healthcare Japan, Tokyo, Japan), and sequencing was performed with 
Big Dye Terminator sequencing kit version 3.1 (Life Technologies, Foster City, CA) on an 
ABI3100 automated sequencer (Life Technologies). We prepared five negative controls (w/o 
tissue section) per 96 samples to ensure contamination-free amplifications. 
 
Genotyping 
Genotyping was performed for PTC cases using the ABI TaqMan SNP assays (Life 
Technologies) in accordance with the manufacturer’s guidelines. A pre-designed and functionally 
tested probe for rs965513 (C_1593670_20) and rs944289 (C_1444137_10) were used. The 
conditions were denaturation at 95℃ for 10 minutes followed by 50 cycles of 92℃ for 15 
seconds and 60℃ for 1 minute for both probes. 
As control subjects, genotypes of rs965513 and rs944289 were extracted from the genome scan 
results using Illumina Human610-Quad BeadChip of 2,766 healthy Japanese individuals 
(mean±SD age 50.1±15.4 years, range 20-79 years; 63.1% women). 
 
Statistical analysis 
A case-control association in each study was examined using trend exact test to compare 
genotypic distributions between cases and controls.[13] A subtype analysis was performed based 
on the BRAF mutational status (BRAF mutant versus control, and BRAF wild-type versus 
control), and the homogeneity of the odds ratios between the two studies was examined with the 
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Breslow-Day test.[14] For each case-control study, p-values and ORs adjusted for age and sex 
were calculated using multiple logistic regression analyses. Haplotype frequency was calculated 




DNA samples extracted from 507 PTC tissues were genotyped by TaqMan assay for rs965513 
and rs944289 (Table 1). Genotyping success rates for cases were 479/507 (94.5%) and 467/507 
(92.1%) for rs965513 and rs944289, respectively. As for controls, the genotyping results that 
could be extracted from the genome scan data were 2,764/2,766 (99.9%) and 2,766/2,766 
(100%) for rs965513 and rs944289, respectively. The genotype distributions of the two SNPs 
conformed to Hardy-Weinberg equilibrium both in cases and in controls. A case-control 
association was examined using trend exact test to compare the genotypic distributions. 
Significant associations were obtained for both SNPs (rs965513: p=1.27×10-4, OR=1.69, 95% 
CI: 1.29-2.21; rs944289: p=0.0121, OR=1.21, 95% CI: 1.04-1.39) (Table 2). Our results 
confirmed the previously reported risk alleles, namely, allele A for rs965513 and allele T for 
rs944289. 
 
We next screened for BRAF mutation in PTC tissues by DNA sequencing. Out of 507 samples, 
492 (97.0%) were successfully genotyped, of which 388 were found to carry a heterozygous 
BRAFV600E mutation, and 104 were negative for the mutation (Table 1). Subgroup analysis based 
on the BRAF mutational status showed a strong association for rs965513 between 381 
BRAFV600E-positive cases and 2,766 controls (p=2.26×10-4, OR=1.72, 95% CI: 1.29-2.29) (Table 
2). On the other hand, no statistically significant association was found between 95 
BRAFV600E-negative cases and controls (p=0.143, OR=1.52, 95% CI: 0.87-2.65), although there 
was no reversal of the risk allele and a similar trend was observed (Table 2). There was no 
difference in the observed effect size between the BRAFV600E-positive and BRAFV600E-negative 
groups (p=0.615). 
 
For rs944289, both analyses showed marginal association (p=0.0585, OR=1.17, 95% CI: 
0.99-1.37 for BRAFV600E-positive cases, and p=0.0492, OR=1.35, 95% CI: 1.00-1.81 for 
BRAFV600E-negative cases) (Table 2). Again, there was no reversal of the risk allele, and there 
was no difference in the observed effect size between the BRAFV600E-positive and 




Here, we report for the first time an association between the FOXE1 gene and PTC in the 
Japanese population by genotyping rs965513 located 57-kb upstream to the FOXE1 gene. The 
association of the FOXE1 gene has been previously demonstrated by a GWA study for sporadic 
PTC[2] as well as for radiation-related PTC[3] in European populations. Furthermore, a recent 
study using an SNP panel of 97 genes related to thyroid cell differentiation and proliferation 
identified rs1867277, a causal SNP within the FOXE1 5’ UTR, functioning as a genetic risk 
factor associated with susceptibility to PTC.[16] The sequence containing the risk allele was 
demonstrated to recruit the USF1/USF2 transcription factors which in turn increased FOXE1 
transcriptional activity. Indeed, animal model experiments have shown that mice lacking the 
FOXE1 locus exhibit neonatal hypothyroidism that shows similarity to thyroid dysgenesis in 
humans.[17] We additionally genotyped rs1867277 in 64 randomly selected cases in our series to 
estimate LD with rs965513. There was no strong evidence for LD between these two SNPs 
(D’=0.23), suggesting that the functional significance of rs965513 may be different from that of 
rs1867277. 
 
The association between NKX2-1 at chromosome 14q13.3 and sporadic PTC was also 
successfully reproduced in the Japanese population. However, the association was weaker for 
NKX2-1 compared to FOXE1 in our study in concordance with the results of the Icelandic study. 
Although rs944289 lies in a 249-kb LD region with no known genes, transcription units or 
predicted exons, NKX2-1 is one of the closest genes residing in this region. NKX2-1 is another 
thyroid specific transcription factor, and together with FOXE1, is expressed from early stages of 
thyroid morphogenesis and plays a major role in the development of the thyroid gland. 
Knock-out mice lacking the NKX2-1 gene die at birth because they lack normal thyroid and 
lungs, demonstrating the essential role of the gene in embryonic differentiation of these 
organs.[18] Interestingly, rs944289 was strongly associated with sporadic PTC in the Icelandic 
population[2] as well as in our Japanese series, but not in the Belarusian radiation-related PTC, 
suggesting that this variant may be associated only with sporadic PTC. 
 
The strong association of rs965513 with Japanese PTC was also found between 
BRAFV600E-positive cases and controls (p=2.26×10-4, OR=1.72, 95% CI: 1.29-2.29) but not 
between BRAFV600E-negative cases and controls (p=0.143, OR=1.52, 95% CI: 0.87-2.65). 
However, the effect size is similar between the two groups (p=0.615), and the statistical power is 
relatively low (0.31) in the latter analysis, suggesting that the lack of significance is due to the 
lower minor allele frequency (MAF) of the SNP in the Japanese population (0.090 in cases, 
0.057 in controls) than in Europeans (0.462-0.490 in cases, 0.352-0.367 in controls),[2, 3] and/or 
the much smaller number of BRAFV600E-negative cases (n=95). On the other hand, a marginal 
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association was observed for rs944289 in both subgroups (p=0.0585, OR=1.17, 95% CI: 
0.99-1.37 for BRAFV600E-positive subgroup and p=0.0492, OR=1.35, 95% CI: 1.00-1.81 for 
BRAFV600E-negative subgroup). Again, the effect size is similar between the two groups 
(p=0.455). However, for both SNPs, the number of BRAFV600E-negative cases needs to be 
increased to draw significant conclusions in the subtype analyses, especially for rs965513 for 
which the MAF in the Japanese population is so much lower compared to Europeans.  
 
In conclusion, our study successfully confirms the association of both rs965513 and rs944289 
with sporadic PTC in the Japanese population. Conceivably, FOXE1 is likely to be the most 
important genetic determinant of susceptibility to PTC regardless of ethnicity. There was no clear 
difference in genetic impact for either of the SNPs with BRAFV600E status. 
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Table 1. Specification of the DNA collections recruited for the study 
 
Sample Number Age (Mean±SD) Age range %Male 
Cases 507 51.3±16.0 13-87 15.6 
    BRAFV600E (+) 388 52.4±15.5 17-87 16.1 
    BRAFV600E (-) 104 48.1±17.2 13-81 13.6 
    Not available 15 - - - 
     
Controls 2,766 50.1±15.4 20-79 36.9 
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p-value3 p-value4 OR (95% CI)5 Power6
[ref/var]1 Case2 Cont Case Cont Case Cont
rs965513 All cases  479 2,764 0.090 0.057 0.255 0.721 1.27 x 10-4 1.69 (1.29-2.21) 0.76 
[A*/G] BRAFV600E (+) 381 2,764 0.092 0.057 0.113 0.721 2.26 x 10-4  1.72 (1.29-2.29) 0.69 
  BRAFV600E (-) 95 2,764 0.079 0.057 1.000 0.721 0.143 1.52 (0.87-2.65) 0.31 
rs944289 All cases 467 2,766 0.466 0.411 0.306 0.695 0.0121 1.21 (1.04-1.39) 0.60 
[C/T*] BRAFV600E (+) 373 2,766 0.458 0.411 0.118 0.695 0.0585 1.17 (0.99-1.37) 0.52 
  BRAFV600E (-) 93 2,766 0.489 0.411 0.411 0.695 0.0492 1.35 (1.00-1.81) 0.19 
1The reference (ref) and variant (var) alleles refer to NCBI Build 36.3, and the risk allele is 
indicated by an asterisk. 
2BRAF mutational statuses were not available in three samples of 479 cases successfully typed 
for rs965513 and in one sample of 467 cases successfully typed for rs944289. 
3The Exact p-values for Hardy-Weinberg equilibrium (HWE) are shown. 
4The p-values using Trend Exact test adjusted for age and sex are shown. 
5Odds ratios (OR) are calculated for the risk allele with a 95% confidence interval (CI). 
6Statistical power is calculated by using power function in Hmisc package 
(http://cran.r-project.org/web/packages/Hmisc/index.html) of R. 
 
 
